Main Uses of Talazoparib

Talazoparib is a targeted therapy medication used primarily in the treatment of specific types of advanced breast cancer. It belongs to a class of drugs known as PARP inhibitors. Its application is focused on patients who have inherited mutations in the BRCA1 or BRCA2 genes.

Targeted Breast Cancer Treatment

Talazoparib is indicated for patients with HER2-negative locally advanced or metastatic breast cancer. This means the cancer has either spread significantly within the breast and surrounding tissues or has traveled to other parts of the body.

The use of this medication is contingent upon the presence of a germline BRCA mutation. These genetic markers are identified through specialized testing before the treatment is initiated.

Emerging Applications

Beyond breast cancer, research has expanded to include the use of talazoparib in combination with other therapies for certain types of advanced prostate cancer. Specifically, it is utilized for metastatic castration-resistant prostate cancer (mCRPC) in adult patients whose tumors exhibit specific gene mutations that affect DNA repair.

Benefits and Mechanism of Action

Talazoparib works by blocking the activity of poly (ADP-ribose) polymerase (PARP), an enzyme that helps cells repair damaged DNA.

Selective Targeting of Cancer Cells

In patients with BRCA mutations, cancer cells already have a weakened ability to repair their DNA. By inhibiting the PARP enzyme, talazoparib further prevents these cells from fixing DNA breaks. This leads to a level of DNA damage that the cancer cells cannot survive, eventually causing cell death. Because this mechanism exploits a specific weakness in the cancer's genetic makeup, it is considered a targeted approach.

Clinical Advantages

• Progression-Free Survival: Clinical studies have shown that talazoparib can extend the amount of time a patient lives without the cancer worsening compared to standard chemotherapy.
• Quality of Life: As an oral medication taken in tablet form, it offers a different administration route than intravenous treatments, which may be more convenient for some patients.
• Objective Response Rate: The medication has demonstrated the ability to shrink tumors or stop their growth in a significant percentage of patients with the relevant genetic mutations.

Regulatory References

1. NIH DailyMed drug information

Talazoparib is indicated for use in adult patients with specific genetic mutations (gBRCAm or HRR gene mutations). Official regulatory labeling defines several limitations and absolute exclusions regarding its use.

Populations Prohibited from Use

• Hypersensitivity: The medicine is contraindicated in patients with a known hypersensitivity to Talazoparib or any of its excipients.
• Reproductive Status: It is contraindicated for use in pregnant women due to the potential for fetal harm, and in women who are breastfeeding.

Conditional Eligibility and Restrictions

Use in patients with very poor kidney function (creatinine clearance <15 mL/min) or those requiring dialysis has not been studied.

Talazoparib Interactions with other medicines and products

The official interaction profile for talazoparib is primarily defined by pharmacokinetic constraints related to drug transporters, specifically the P-glycoprotein (P-gp) efflux transporter. Interactions are officially categorized as clinically significant due to their substantial effect on drug exposure, requiring specific management or avoidance.

Co-administration with strong P-gp inhibitors is a major interaction concern and must be avoided whenever possible. These inhibitors, which include medicines like itraconazole, amiodarone, carvedilol, clarithromycin, and verapamil, can interfere with P-gp. This inhibition leads to a significant increase in talazoparib exposure (AUC) by 45% to 56%. If such co-administration is unavoidable, a dose reduction is a mandatory regulatory constraint.

The regulatory documents also advise that concomitant use with strong BCRP inhibitors should be avoided due to the potential for increased systemic exposure. In contrast, P-gp inducers (like rifampin) are documented to increase the maximum plasma concentration (C max) but do not significantly alter overall exposure (AUC).

A population-specific restriction notes that patients with moderate or severe renal impairment (creatinine clearance less than 60 mL/min) require a reduced starting dose. This is necessary because impaired renal function alters drug clearance, resulting in heightened exposure. Lastly, the official prescribing information states that talazoparib may be taken with or without food, and co-administered with acid-reducing agents, without a documented clinically significant interaction.

Talazoparib's mechanism relies on a dual-action strategy known as synthetic lethality, which is dependent on the intrinsic DNA repair status of the target cells. The drug is an inhibitor of the nuclear enzymes Poly(ADP-ribose) polymerase (PARP1 and PARP2). Its action involves both catalytic inhibition (blocking the enzyme's function in Single-Strand Break Repair, or SSBR) and a critical cellular effect called PARP trapping. This trapping physically immobilizes the PARP enzyme onto the DNA break site, forming stable lesions that act as a physical roadblock to the cell’s DNA replication machinery. The resulting cytotoxicity relies on exploiting a pre-existing deficiency in the cell’s primary backup system, the Homologous Recombination Repair (HRR) pathway (often due to BRCA mutations). When Talazoparib causes the SSBR pathway to fail, the unrepaired single-strand damage is converted into lethal Double-Strand Breaks (DSBs) during DNA replication. Because the HRR system is deficient, the cell is faced with irreparable damage, which triggers apoptosis. This sequence leads to genomic instability primarily in HRR-deficient cells.

Talazoparib is administered by the oral route as a hard capsule, on a continuous, once-daily schedule until the disease progresses or the patient experiences unacceptable physiological responses. The hard capsules must be swallowed whole and should not be opened or dissolved to avoid contact with the contents. Intake is permitted with or without food.

Standard Dosage Regimens

The starting dose depends on the patient's indication:

Dose Adjustments and Duration

Treatment duration is defined by clinical response, continuing until disease progression or the need for cessation due to physiological constraint. There are defined dose reduction levels that are followed if adverse reactions occur. Treatment with Talazoparib is discontinued if more than three dose reductions are required.

For patients with moderate renal impairment (CrCL 30–59 mL/min), the starting dose is reduced to 0.75 mg daily for monotherapy, or 0.35 mg daily for combination use. A further reduction is mandated for severe renal impairment (CrCL 15–29 mL/min). No initial dose adjustment is required for older adults (age 65 years and over).

If a dose is missed or vomited, an additional dose must not be taken; the patient should simply take the next prescribed dose at the usual scheduled time.

Talazoparib: Recent Clinical Evidence

Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that has been investigated across multiple clinical trials, primarily for treating cancers with BRCA-mutations and other homologous recombination repair (HRR) deficiencies.

Efficacy and Study Outcomes

Research has focused on determining the progression-free survival (PFS) and overall response rates (ORR) associated with talazoparib treatment. In studies involving patients with locally advanced or metastatic BRCA-mutated breast cancer, trial data reported a longer median PFS for participants receiving talazoparib monotherapy compared to those receiving standard chemotherapy. These findings contributed to the drug's regulatory review in this setting.

Studies have also evaluated the drug's use in combination with standard anti-cancer therapies, such as platinum-based chemotherapy and endocrine treatments. In trials for specific types of prostate cancer, the combination of talazoparib with a novel androgen receptor inhibitor was observed to extend radiographic PFS compared to the control regimen.

Safety and Tolerability Profile

Across clinical trials, talazoparib has a distinct safety profile, primarily characterized by hematological adverse events. The most frequently reported adverse events include anemia, neutropenia, and thrombocytopenia. Researchers and clinicians manage these effects through dose modifications and supportive care. Non-hematological adverse events commonly reported in the study data include fatigue and nausea. The overall discontinuation rates due to adverse events remain a focus of ongoing research and patient management.

Key Studies & References

1. Talazoparib in Patients with Advanced gBRCA-mutated Breast Cancer: Final Overall Survival Results from the EMBRACA Trial
2. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
3. FDA Approves Talazoparib in Combination with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer (Based on TALAPRO-2 trial)

Common questions about Talazoparib (FAQ)

Q: Is feeling very tired (fatigue) a common side effect of Talazoparib?

Yes, official safety documents list fatigue (or asthenia) as a Very Common adverse reaction. This classification means it is reported to affect more than 1 in 10 patients in clinical study data. It is one of the most frequently reported non-blood-related effects of the medicine.

Q: Can Talazoparib cause problems with my blood counts?

Official safety documents indicate that the medicine commonly affects blood production, a condition known as myelosuppression. This frequently results in low levels of red blood cells (Anemia), certain white blood cells (Neutropenia), and platelets (Thrombocytopenia).

Q: Are there any common foods or drinks that interact with Talazoparib?

Regulatory information states that Talazoparib may be taken with or without food. Official documents focus on interactions with certain medicines and do not list any specific common foods or drinks that require avoidance or a mandatory dose change.

Q: Does Talazoparib affect kidney function?

Official documentation requires a dose reduction for patients who already have moderate or severe renal impairment (impaired kidney function). This adjustment is necessary because impaired kidney function can change how the drug is cleared from the body.

Q: How does Talazoparib affect my ability to drive or operate machinery?

Talazoparib is described as having a minor influence on the ability to drive and use machines. This warning is included because side effects such as fatigue or dizziness are reported to occur during treatment.

Q: What is the maximum duration of treatment with Talazoparib described in studies?

Treatment duration is generally defined by the patient's clinical response, continuing until the disease progresses or unacceptable physiological side effects occur, as detailed in regulatory guidance and clinical trials. No specific maximum duration is defined in the official prescribing information.

Q: What is the general success rate mentioned in clinical trials for Talazoparib?

Clinical trials evaluate the medicine based on outcomes like survival and progression. Studies have demonstrated a statistically significant improvement in measures such as progression-free survival (PFS) and radiographic PFS in the indicated patient populations compared to control groups.

Q: What is the evidence that Talazoparib helps with BRCA-mutated breast cancer?

Clinical trial data showed that participants with locally advanced or metastatic BRCA-mutated breast cancer who received Talazoparib monotherapy experienced a longer median progression-free survival (PFS) compared to those who received standard chemotherapy.

Q: Can Talazoparib be used to treat cancers other than breast cancer?

Yes, it is approved for use in combination with enzalutamide for the treatment of adult patients with specific genetic changes. This indication is for HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Q: Why do some people take Talazoparib with another drug like Enzalutamide?

The medicine is indicated for treating HRR gene-mutated metastatic castration-resistant prostate cancer when used in combination with enzalutamide. This combination use is based on supporting clinical trial data that evaluated the two medicines together in this specific setting.

Q: Does Talazoparib affect healthy cells in the body?

Although it is described as a targeted therapy, the safety profile shows that the medicine commonly affects healthy blood cells, causing Myelosuppression. This results in low levels of red blood cells, white blood cells, and platelets.

Q: Does Talazoparib interact with common over-the-counter pain relievers?

Official drug interaction information focuses on medicines that strongly inhibit certain drug transporters, such as P-glycoprotein (P-gp) inhibitors. Regulatory documents do not specifically list common over-the-counter pain relievers as requiring a mandated dose change or avoidance.

Q: Is it safe to take supplements or vitamins while on Talazoparib?

The official product label states that all patients should inform their healthcare provider about all prescription and over-the-counter medicines, vitamins, and herbal supplements they are taking. This is noted due to the potential for interactions that could affect Talazoparib exposure.

Q: Does Talazoparib interact with alcohol?

The official prescribing information does not list a specific contraindication with alcohol. One general patient information source noted that it is unknown if consuming alcohol affects the medicine.

Q: What should I know about pregnancy and taking Talazoparib?

Talazoparib is contraindicated in pregnant women because regulatory data indicates the potential for fetal harm. Regulatory documents state that women of reproductive potential are required to use effective contraception during treatment and for 7 months after the final dose.

Q: Can men use Talazoparib?

Yes, Talazoparib is indicated for use in adult patients, including those with prostate cancer. Official guidance specifies that males with female partners capable of becoming pregnant are required to use effective contraception during treatment and for 4 months after the final dose.

Q: Are there age limits for using Talazoparib?

The medicine is indicated for use in adult patients. Safety and efficacy in pediatric patients (under 18) have not been established. No initial dose adjustment is required for older adults (65 years and over).

Q: Is Talazoparib treatment given in a hospital setting?

Talazoparib is supplied as an orally available hard capsule, designed to be taken once daily. This method of administration is typically consistent with a treatment regimen managed outside of a hospital setting.

Q: Can Talazoparib be taken by people who have had a blood transfusion?

The official label specifies that treatment is not to be initiated until recovery from prior hematological toxicity (such as low blood counts) has returned to a specified safe level (leq Grade 1).

Q: Does Talazoparib have a risk of causing a secondary cancer?

Official safety warnings note the risk of developing Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML), which are types of secondary malignancies. These have been reported in a small number of patients treated with the medicine.

Q: Can Talazoparib be taken by people with certain pre-existing medical conditions?

Official labeling indicates that specific dose adjustments or restrictions apply to patients with pre-existing moderate or severe renal impairment or severe hepatic impairment (in combination therapy).

Q: What are the research findings on Talazoparib's use in prostate cancer?

In clinical trials for HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC), the combination of Talazoparib with Enzalutamide demonstrated a statistically significant improvement in radiographic progression-free survival (rPFS) compared to the control group.

Q: Does Talazoparib require refrigeration or special storage?

Talazoparib capsules must be stored at Controlled Room Temperature (20^circC to 25^circC), meaning refrigeration is not required. The capsules must be kept protected from moisture in the original, tightly closed bottle.

Q: What happens in the body when PARP is inhibited?

Inhibition of the PARP enzyme (PARP1 and PARP2) leads to a dual effect: it blocks a key DNA repair pathway and causes PARP trapping onto damaged DNA sites. This results in potentially lethal damage to cancer cells that have specific genetic defects.

Q: Do people who take Talazoparib feel generally ill?

The official adverse reaction profile frequently lists several general symptoms as Very Common events. These include fatigue/asthenia, nausea, and vomiting, which are often associated with generally feeling unwell.

Q: Is Talazoparib used in early-stage cancer treatment?

Official regulatory indications are for locally advanced or metastatic breast cancer and metastatic castration-resistant prostate cancer. This indicates the medicine is not generally authorized for the treatment of early-stage disease.

Q: What does it mean if Talazoparib is described as a targeted therapy?

Talazoparib is classified as a PARP inhibitor that uses a principle called synthetic lethality. This means the medicine is designed to target and destroy cancer cells that have specific defects in their DNA repair systems, such as BRCA mutations.

Q: Can I take Talazoparib if I have a history of bone marrow problems?

The official label specifies that treatment is not to be initiated until recovery from prior hematological toxicity (such as low blood counts) has returned to a specified safe level (leq Grade 1). Additionally, patients with a history of Myelodysplastic Syndrome or Acute Myeloid Leukemia are noted as a specific safety risk.

Storage and Disposal of Talazoparib

Talazoparib capsules must be stored at Controlled Room Temperature, officially defined as 20°C to 25°C (68 F to 77 F), with permitted excursions up to 30 C.

The medication must not be used after the printed expiry date. All unused Talazoparib capsules and related waste must be disposed of in accordance with local and national regulations for pharmaceutical waste, and must not be placed in household trash or poured down a drain.